Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint TherapyXinqi Wu, F. Stephen Hodi, Michael P. Manos et al.|Cancer Immunology Research|2016Cited by 167
Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical OutcomesXinqi Wu, F. Stephen Hodi, Jingjing Li et al.|Cancer Immunology Research|2017Cited by 68
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanomaXinqi Wu, F. Stephen Hodi, Anita Giobbie‐Hurder et al.|OncoImmunology|2018Cited by 40